Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Or leave a message with a formal purchase order (PO) Or credit card.
Hybridoma Generation for Therapeutic Antibody Discovery Services
Combination of mice with various genetic background, such as white, mice, immunodeficiency, knock-out, and humanized, can be used for hybridoma development for antibody drug discovery and screening.
The most comprehensive hybridoma generation for therapeutic antibody services:
Applications: drug, diagnostics, or CAR T;
Genetic background: white, mice, immunodeficiency, knock-out, and humanized mice; rat; hamster;
Antigens: proteins, peptides, DNA, cells expressing certain proteins.
BS023A: a standard program for mouse hybridoma generation for therapeutic antibody discovery.
Phase I: Immunization and boosts of 5 Balb/c mice, 3 following the repetitive immunizations multiple sites or RIMMS protocol and 2 following the standard immunization protocol, and ELISA screening of mouse polyclonal sera.
Phase II: Electrofusion of splenocytes to mouse myeloma cells and ELISA screening to isolate antigen-positive hybridoma cells from an initial count of about 30000 fusion clones. Supernatant (conditioned media) from the final ELISA-positive clone population pools will be sent to clients for evaluation of specific applications.
Phase III: Subcloning of the ELISA-positive clone population pools by limited dilution to isolate individual hybridoma clones of interest, and expansion of the individual hybridoma clones.
You provide: 20 mg of peptide (purity > 85%, length > 12 amino acids) or 10 mg of soluble protein (concentration > 0.4 mg/ml, purity > 90%, molecular weight > 20 kDa) for immunization and screening.
* About 80 ul supernatant from 50-100 ELISA positive cells for evaluation;
* 10 positive hybridoma cell lines;
* Remaining antigens;
* ELISA results.
Clients have the choice for licensing antibodies to save cost and even make money.
The prices will be adjusted for the following requirements:
a. Peptide (12-15 amino acids, >85%) design and synthesis +$500;
b. Synthesis of other antigens, +$variable;
c. Conjugation of antigens to protein carriers +$150;
d. Protein: DNA subcloning +$400, bacterial expression and purification +$2,500;
f. Additional positive hydridoma cell line +$400.
Syd Labs also provides other monoclonal antibody development services:
After great hybridoma clones have been developed, if clients want to file patents, protect the antibodies using the digital format, or develop antibody drugs, clients can ask us to clone and sequence the hybridoma antibody variable regions (VH and VL), do transient expression of chimeric antibodies (scFv or complete IgG) in CHO or HEK293 cells, or generate stable cell line expressing antibodies.